This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, W.
Right arrow Articles by Sei, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, W.
Right arrow Articles by Sei, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2005, p. 4965-4973, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.4965-4973.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Potent Antiviral Activity of North-Methanocarbathymidine against Kaposi's Sarcoma-Associated Herpesvirus

Weimin Zhu,1,{dagger} Angela Burnette,1,{ddagger} Dorjbal Dorjsuren,1,{dagger} Paula E. Roberts,1,§ Mahmoud Huleihel,2 Robert H. Shoemaker,3 Victor E. Marquez,4 Riad Agbaria,5 and Shizuko Sei1*

Laboratory of Antiviral Drug Mechanisms, SAIC-Frederick, Frederick, Maryland,1 National Institute for Biotechnology and Department of Virology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel,2 Screening Technologies Branch, Developmental Therapeutics Program, NCI-Frederick, Frederick, Maryland,3 Laboratory of Medicinal Chemistry, Center for Cancer Research, NCI-Frederick, Frederick, Maryland,4 Department of Clinical Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel5

Received 26 April 2005/ Returned for modification 31 July 2005/ Accepted 19 September 2005

Kaposi's sarcoma-associated herpesvirus (KSHV) infection is a prerequisite for the development of Kaposi's sarcoma (KS). Blocking lytic KSHV replication may hinder KS tumorigenesis. Here, we report potent in vitro anti-KSHV activity of 2'-exo-methanocarbathymidine [North-methanocarbathymidine (N-MCT)], a thymidine analog with a pseudosugar ring locked in the northern conformation, which has previously been shown to block the replication of herpes simplex virus types 1 and 2. N-MCT inhibited KSHV virion production in lytically induced KSHV-infected BCBL-1 cells with a substantially lower 50% inhibitory concentration (IC50) than those of cidofovir (CDV) and ganciclovir (GCV) (IC50, mean ± standard deviation: 0.08 ± 0.03, 0.42 ± 0.07, and 0.96 ± 0.49 µM for N-MCT, CDV, and GCV, respectively). The reduction in KSHV virion production was accompanied by a corresponding decrease in KSHV DNA levels in the N-MCT-treated BCBL-1 cells, indicating that the compound blocked lytic KSHV DNA replication. A time- and dose-dependent accumulation of N-MCT-triphosphate (TP) was demonstrated in lytically induced BCBL-1 cells, while uninfected cells showed virtually no accumulation. The levels of N-MCT-TP were significantly decreased in the presence of 5'-ethynylthymidine, a potent inhibitor of herpesvirus thymidine kinase, resulting in the abrogation of anti-KSHV activity of N-MCT. N-MCT-TP more effectively blocked in vitro DNA synthesis by KSHV DNA polymerase with an IC50 of 6.24 ± 0.08 µM (mean ± standard deviation) compared to CDV-diphosphate (14.70 ±2.47 µM) or GCV-TP (24.59 ± 5.60 µM). Taken together, N-MCT is a highly potent and target-specific anti-KSHV agent which inhibits lytic KSHV DNA synthesis through its triphosphate metabolite produced in KSHV-infected cells expressing a virally encoded thymidine kinase.

* Corresponding author. Present address: Laboratory of Human Toxicology & Pharmacology, Developmental Therapeutics Program, SAIC/NCI-Frederick, Bldg. 439, P. O. Box B, Frederick, MD 21702. Phone: (301) 846-1780. Fax: (301) 846-6067. E-mail: sei{at}ncifcrf.gov.

{dagger} Present address: Laboratory of Human Toxicology & Pharmacology, Developmental Therapeutics Program, SAIC/NCI-Frederick, Frederick, Md.

{ddagger} Present address: SuperArray Bioscience Corporation, Frederick, Md.

§ Present address: Southern Research Institute, Frederick, Md.

Antimicrobial Agents and Chemotherapy, December 2005, p. 4965-4973, Vol. 49, No. 12
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.12.4965-4973.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Prichard, M. N., Keith, K. A., Quenelle, D. C., Kern, E. R. (2006). Activity and Mechanism of Action of N-Methanocarbathymidine against Herpesvirus and Orthopoxvirus Infections.. Antimicrob. Agents Chemother. 50: 1336-1341 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»